Intra-Cellular Therapies, Inc. ITCI
Trading inactive
Analyst Consensus
Price Objectif
Analyst historical
| Analyste | Entreprise | Prix lors de l'analyse | Prix cible | Gain potentiel | Date de publication |
|---|---|---|---|---|---|
| David Amsellem | Piper Sandler | 83.23 $ | 132 $ | 48.77 % | 14/01/2025 |
| Corinne Jenkins | Goldman Sachs | 85.47 $ | 79 $ | -6.47 % | 30/10/2024 |
| David Amsellem | Piper Sandler | 72.42 $ | 92 $ | 19.58 % | 05/09/2024 |
| Brian Abrahams | RBC Capital | 73.63 $ | 106 $ | 32.37 % | 08/08/2024 |
| Corinne Jenkins | Goldman Sachs | 73.63 $ | 74 $ | 0.37 % | 07/08/2024 |
| Ami Fadia | Needham | 74.86 $ | 100 $ | 25.14 % | 22/07/2024 |
| Ashwani Verma | UBS | 72.42 $ | 83 $ | 10.58 % | 25/06/2024 |
| Graig Suvannavejh | Mizuho Securities | 76.06 $ | 100 $ | 23.94 % | 20/06/2024 |
| Brian Abrahams | RBC Capital | 75.48 $ | 103 $ | 27.52 % | 18/06/2024 |
| Brian Abrahams | RBC Capital | 71.21 $ | 96 $ | 24.79 % | 07/05/2024 |
| Andrew Tsai | Jefferies | 70.075 $ | 105 $ | 34.93 % | 07/05/2024 |
| Sumant Kulkarni | Canaccord Genuity | 74.54 $ | 107 $ | 32.46 % | 23/04/2024 |
| Joel Beatty | Robert W. Baird | 79.84 $ | 103 $ | 23.16 % | 17/04/2024 |
| Ami Fadia | Needham | 67.21 $ | 82 $ | 14.79 % | 05/04/2024 |
| Ashwani Verma | UBS | 53.07 $ | 75 $ | 21.93 % | 13/06/2022 |
| Corinne Jenkins | Goldman Sachs | 57.49 $ | 64 $ | 6.51 % | 17/02/2022 |